AMG 811 ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
49 | 全身性エリテマトーデス | 3 |
49. 全身性エリテマトーデス
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01164917 (ClinicalTrials.gov) | August 2010 | 15/7/2010 | Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus | A Randomized, Double-blind, Placebo-controlled, Single Dose, Two-period, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of AMG 811 in Subjects With Discoid Lupus Erythematosus | Cutaneous Lupus;Discoid Lupus;Lupus;Systemic Lupus Erythematosus | Drug: AMG811;Drug: AMG811 Placebo | Amgen | NULL | Terminated | 18 Years | 70 Years | Both | 16 | Phase 1 | United States |
2 | NCT00818948 (ClinicalTrials.gov) | March 2009 | 18/12/2008 | Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis | A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis | Nephritis;Systemic Lupus Erythematosus | Drug: AMG 811 | Amgen | NULL | Completed | 18 Years | 70 Years | Both | 56 | Phase 1 | United States;France;Hong Kong;Malaysia;Mexico;Singapore |
3 | NCT02291588 (ClinicalTrials.gov) | December 2007 | 3/11/2014 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus | A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: AMG 811;Drug: Placebo | Amgen | NULL | Completed | 18 Years | 65 Years | Both | 26 | Phase 1 | NULL |